Accelerating cancer discovery through spatial pathology

Even in the most common cancers—breast, bowel, prostate, lung—new biomarkers take decades to move from discovery to routine clinical use.

The bottleneck isn't scientific understanding. It's the air gap between clinical pathology laboratories and the research and pharmaceutical teams who need their data to discover, validate, and deploy new molecular markers.

Clinical labs generate extraordinary volumes of tissue data every day, but it stays locked in formats and systems designed for individual patient care—not for the large-scale analysis that drives discovery. Research teams work with small, painstakingly curated cohorts while population-scale insights remain inaccessible.

The result is a slow, fragmented pipeline where promising biomarkers languish for years between initial discovery and clinical validation.